Exactly how that degradation takes place, how an RNA virus can preserve its integrity when it makes a protein that breaks down RNA, and whether a mutated non-RNA-degrading SARS coronavirus could constitute a workable SARS vaccine are all issues that Makino's group intends to pursue. "The main concern for everybody is whether SARS will come back," Makino said. "We want to be ready for it if it does."